Public Sector Pension Investment Board Acquires 28,236 Shares of Enovis Corporation $ENOV

Public Sector Pension Investment Board increased its holdings in shares of Enovis Corporation (NYSE:ENOV) by 14.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 222,939 shares of the company’s stock after purchasing an additional 28,236 shares during the quarter. Public Sector Pension Investment Board owned 0.39% of Enovis worth $6,764,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Tributary Capital Management LLC boosted its stake in Enovis by 91.5% in the 3rd quarter. Tributary Capital Management LLC now owns 1,154,482 shares of the company’s stock worth $35,027,000 after purchasing an additional 551,613 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Enovis by 682.6% in the second quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after purchasing an additional 434,646 shares in the last quarter. Boston Partners grew its holdings in shares of Enovis by 42.4% during the second quarter. Boston Partners now owns 1,382,724 shares of the company’s stock worth $43,352,000 after buying an additional 411,744 shares in the last quarter. Geode Capital Management LLC raised its position in Enovis by 43.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,342,481 shares of the company’s stock valued at $42,105,000 after buying an additional 408,608 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY lifted its stake in Enovis by 41.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company’s stock valued at $34,913,000 after acquiring an additional 326,900 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ENOV shares. BTIG Research assumed coverage on shares of Enovis in a research note on Tuesday, January 6th. They set a “buy” rating and a $41.00 price target for the company. UBS Group reissued a “buy” rating and set a $50.00 price target on shares of Enovis in a research report on Monday, January 5th. Wells Fargo & Company lifted their target price on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Evercore reissued an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Finally, Canaccord Genuity Group dropped their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Insider Buying and Selling

In other news, EVP Daniel A. Pryor sold 999 shares of the stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John Kleckner acquired 2,468 shares of the stock in a transaction on Tuesday, November 25th. The shares were purchased at an average price of $30.32 per share, for a total transaction of $74,829.76. Following the transaction, the insider directly owned 12,302 shares in the company, valued at approximately $372,996.64. This trade represents a 25.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 2.70% of the stock is currently owned by company insiders.

Enovis Stock Performance

NYSE ENOV opened at $22.08 on Thursday. The stock has a market cap of $1.26 billion, a PE ratio of -0.93 and a beta of 1.52. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. The firm has a 50-day moving average of $24.77 and a 200-day moving average of $28.39. Enovis Corporation has a 52-week low of $21.00 and a 52-week high of $44.76.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.